Venlafaxine

CHEMBL637 Phase 4 Onaylandı Small molecule
Half-Life
5 hours
Bioavailability
Protein Binding
Molecular Weight
277.4 g/mol
LogP
2.9
Phase
4

A serotonin-norepinephrine reuptake inhibitor, venlafaxine raises brain levels of both neurotransmitters to help regulate mood and anxiety. It treats major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. Marketed as Effexor, it has the formula C17H27NO2. Because it can raise blood pressure, particularly at higher doses, treatment is accompanied by blood-pressure monitoring, and abrupt discontinuation can produce withdrawal symptoms.

This serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood and anxiety. Blood pressure should be monitored as it can cause small increases, particularly at higher doses.

Moleküler Ağırlık

277,4020 g/mol

LogP

2,90

TPSA

32,70 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

İlaç Sınıfları

Etki Mekanizması

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Pharmacokinetics (PK)

Half-Life 5 hours

Pharmacodynamics (PD)

Mekanizma

Serotonin-norepinephrine reuptake inhibitor (SNRI).

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1

InChI

InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3

Molecular Formula

C17H27NO2

HBD / HBA

1 / 3

Döndürülebilir Bağlar

5

Ağır Atomlar

20

Primary Target

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. It works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood and anxiety. Blood pressure should be monitored as it can cause small increases, particularly at higher doses.

Serotonin-norepinephrine reuptake inhibitor (SNRI).

Key pharmacokinetic parameters for Venlafaxine: Half-life: 5 hours.

Yes, Venlafaxine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL637. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5656. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.